انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
Aug 30 2024 This Week in Cardiology
Manage episode 437152930 series 2291284
From ESC: post-MI beta blockers, a new therapy for ATTR-CM, holding RASi before non-cardiac surgery, good news in HFpEF, and an ESC preview are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. ABYSS
- ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204
- REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479
II. ATTR -CM HELIOS B
Positive Top Line Results for Vutrisiran in Cardiac Amyloidosis
- HELIOS A https://www.tandfonline.com/doi/full/10.1080/13506129.2022.2091985
- HELIOS B https://www.nejm.org/doi/full/10.1056/NEJMoa2409134
III. STOP or NOT Trial
- Observational Study Showing Benefits of Holding RASi https://doi.org/10.1097/ALN.0000000000001404
- STOP or NOT Protocol Paper -- https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3247-1
- JAMA STOP or NOT https://jamanetwork.com/journals/jama/fullarticle/2823118
IV. GLP1a in HFpEF
The GLP-1 Agonist Semaglutide in HFpEF Cleared a Low Bar https://www.medscape.com/viewarticle/995872
- STEP-HFpEF https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
- STEP-HFpEF-DM https://www.nejm.org/doi/full/10.1056/NEJMoa2313917
- SELECT https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- FLOW https://www.nejm.org/doi/full/10.1056/NEJMoa2403347
- Lancet Meta-analysis https://doi.org/10.1016/S0140-6736(24)01643-X
V. ESC Preview
Mandrola's Five Big Trials to Look for at ESC 2024
https://www.medscape.com/viewarticle/mandrolas-five-big-trials-look-esc-2024-2024a1000fkt
Topline Finerenone Results Point to Advance in Heart Failure
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
332 حلقات
Manage episode 437152930 series 2291284
From ESC: post-MI beta blockers, a new therapy for ATTR-CM, holding RASi before non-cardiac surgery, good news in HFpEF, and an ESC preview are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. ABYSS
- ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204
- REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479
II. ATTR -CM HELIOS B
Positive Top Line Results for Vutrisiran in Cardiac Amyloidosis
- HELIOS A https://www.tandfonline.com/doi/full/10.1080/13506129.2022.2091985
- HELIOS B https://www.nejm.org/doi/full/10.1056/NEJMoa2409134
III. STOP or NOT Trial
- Observational Study Showing Benefits of Holding RASi https://doi.org/10.1097/ALN.0000000000001404
- STOP or NOT Protocol Paper -- https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3247-1
- JAMA STOP or NOT https://jamanetwork.com/journals/jama/fullarticle/2823118
IV. GLP1a in HFpEF
The GLP-1 Agonist Semaglutide in HFpEF Cleared a Low Bar https://www.medscape.com/viewarticle/995872
- STEP-HFpEF https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
- STEP-HFpEF-DM https://www.nejm.org/doi/full/10.1056/NEJMoa2313917
- SELECT https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- FLOW https://www.nejm.org/doi/full/10.1056/NEJMoa2403347
- Lancet Meta-analysis https://doi.org/10.1016/S0140-6736(24)01643-X
V. ESC Preview
Mandrola's Five Big Trials to Look for at ESC 2024
https://www.medscape.com/viewarticle/mandrolas-five-big-trials-look-esc-2024-2024a1000fkt
Topline Finerenone Results Point to Advance in Heart Failure
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
332 حلقات
Все серии
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.